Published in Medical Patent Law Weekly, May 17th, 2006
This agreement allows Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ISA247 in patients suffering from mild to moderate psoriasis.
Under the terms of the agreement, Cellgate Inc. will perform studies to evaluate the feasibility of using their technology to topically deliver ISA247. These studies will commence over the next few months and are expected to be completed over a 1-year period. In exchange...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly